Moderna's Melanoma Vaccine Shows Promise, But Stock Falls Amid High Expectations
Summarized from Ynetnews by baba
Moderna and Merck's experimental personalized melanoma vaccine, combined with Keytruda, reduced the risk of recurrence or death by 42% in a Phase 3 trial. Despite the promising results, Moderna's stock fell nearly 18% due to high investor expectations not being fully met. The companies are targeting a 2027 launch, but regulatory and broader cancer application challenges remain. Oncologists hail the personalized mRNA approach as a significant advancement.
The story in 6 lines · by baba
- Moderna and Merck's melanoma vaccine plus Keytruda cut recurrence or death risk by 42% in a Phase 3 trial.
- Moderna's stock plunged nearly 18% despite positive trial results, driven by unmet Wall Street expectations.
- The personalized mRNA vaccine is custom-made for each patient, targeting unique tumor mutations.
- The companies aim for a potential U.S. launch in 2027, pending regulatory approval.
- Success in melanoma may not translate to other cancers, with further trials ongoing.
- Oncologists view the vaccine as a major step forward in personalized cancer treatment.
Ynetnews publishes in English. The key points are summarized above. Read Ynetnews’s full report from the link at the top of the page.
Mentioned
The same event, reported separately by each outlet. Open a few to compare what different newsrooms emphasize — and what they leave out.
Coverage from Ynetnews
